Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Bayer |
---|---|
Information provided by: | Bayer |
ClinicalTrials.gov Identifier: | NCT00044915 |
The purpose of this trial is to evaluate Repinotan HCl in patients with acute ischemic stroke. At study entry patients will be randomized to Repinotan HCl or placebo in a 1:1 ratio. The total treatment period wil be 72 hours.
Condition | Intervention | Phase |
---|---|---|
Acute Ischemic Stroke |
Drug: Repinotan HCl |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients With Acute Ischemic Stroke |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
PLEASE NOTE: Enrollment has been completed.
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | Protocol No. 100282 |
Study First Received: | September 6, 2002 |
Last Updated: | August 17, 2007 |
ClinicalTrials.gov Identifier: | NCT00044915 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Cerebral Infarction Stroke Vascular Diseases Central Nervous System Diseases |
Ischemia Brain Diseases Cerebrovascular Disorders |
Pathologic Processes Nervous System Diseases Stroke Vascular Diseases Central Nervous System Diseases |
Cardiovascular Diseases Ischemia Brain Diseases Cerebrovascular Disorders |